Sydney Lupkin
speaker
1,087 appearances
111 recordings
3 series
first heard Dec 2024
last heard 2d ago
Sydney Lupkin’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 96 in all, peaking in Sep 2026 with 23.
Appearances
Sydney Lepkin, NPR News.
black box warnings on hormone therapies are the FDA's strongest.
They're used to inform doctors and patients that a drug can cause serious or life-threatening side effects.
The warnings had been on hormone therapies for more than 20 years and say the drugs increased the risk of certain cancers, strokes, and heart attacks.
Now the FDA is removing the warnings, saying those risks were overstated.
It's a change many doctors have urged the FDA to make, but they say the agency didn't follow its usual procedure for doing so.
The FDA convened a special expert panel in July instead of using an existing advisory committee, which follows a stricter process for reviewing evidence and making recommendations.
Sydney Lepkin, NPR News.
Black box warnings on hormone therapies are the FDA's strongest.
They're used to inform doctors and patients that a drug can cause serious or life-threatening side effects.
The warnings had been on hormone therapies for more than 20 years and say the drugs increased the risk of certain cancers, strokes, and heart attacks.
Now the FDA is removing the warnings, saying those risks were overstated.
It's a change many doctors have urged the FDA to make, but they say the agency didn't follow its usual procedure for doing so.
The FDA convened a special expert panel in July instead of using an existing advisory committee, which follows a stricter process for reviewing evidence and making recommendations.
Sydney Lepkin, NPR News.
A lot of the stuff about the obesity drugs is unique to the administration's arrangements with Novo Nordisk and Eli Lilly.
That said, today's deals also included similar terms to deals with Pfizer and AstraZeneca, such as a three-year exemption from certain tariffs.
Sydney Lupkin reporting.
The centerpiece of the deals is blockbuster drugs for type 2 diabetes and obesity, so Ozempic, Wegovi, Manjaro, and Zetbound.
It expands coverage to some but not all Medicare beneficiaries with obesity.
Showing 821–840 of 1,087 · page 42 of 55
← Previous
Next →